The characteristics regarding age, gender, tumor location, pre and post-operative carcino-embryonic antigen (CEA), number of surgeries and response to treatment for patients underlying KRAS gene mutations are mentioned in Table 2. This evidence concerns the gene KRAS and neoplasm.